Gilead Announces Interim Phase 2 Results for GS-9973 in Previously...
The data show that among patients with chronic lymphocytic leukemia who received at least eight weeks of GS-9973 monotherapy, 97 percent experienced a reduction in lymph node size.
Fri Dec 06, 2013
Contra Costa Times
Gilead's breakthrough hepatitis C drug approved by FDA
Federal health officials have approved a highly anticipated hepatitis C drug from Gilead Sciences that is expected to offer a faster, more palatable cure to millions of people infected with the liver-destroying virus.
U.S. Food and Drug Administration Approves Gileada s Sovaldia ...
Sovaldi's efficacy has been established in subjects with hepatitis C virus genotypes 1, 2, 3 or 4 infection, including those with hepatocellular carcinoma meeting Milan criteria and those with HCV/HIV-1 co-infection.
Mon Dec 02, 2013
Gilead Sciences to Present at the Nasdaq Omx 30th Investor Program on Tuesday, December 3
Gilead Sciences, Inc. today announced that its corporate presentation will be webcast from the NASDAQ OMX 30th Investor Program in London.
Gilead Sciences, Inc. Uses the PHT Corporation LogPad System for 1st...
The PHT Corporation LogPad System was used by Gilead Sciences, Inc. on the Phase 4 TERISA trial which measured the antianginal effect of Ranolazine in T2DM patients in the therapeutic areas of cardiology and endocrinology.
Idenix Pharmaceuticals Files Patent Infringement, Interference Lawsuits Against Gilead Sciences
Idenix Pharmaceuticals today announced that it has filed two lawsuits against Gilead Sciences, Inc. : a patent infringement lawsuit in the United States District Court in Boston, Massachusetts and a separate patent infringement and interference lawsuit in the United States District Court in Wilmington, Delaware.
Wed Nov 27, 2013
Early Morning Buzz: Groupon, Gilead Sciences, Eltek Ltd, Alcatel...
There are gimmicks and then there are gimmicks. Groupon, Inc. is out with its gimmick for Black Friday.
Tue Nov 26, 2013
Jefferies Group Increases Gilead Sciences Price Target to $80.00
Jefferies Group's price objective points to a potential upside of 7.24% from the stock's previous close.
San Mateo Daily Journal
Gilead protester sues Foster City police
A woman protesting the high price of AIDS drugs at Gilead Sciences last November claims a Foster City police officer knocked her down with a squad car despite the demonstrators following company requests to leave.
Fri Nov 22, 2013
Customer Interaction Solutions
Stocks Build Momentum as S&P Tops 1,800 For First Time
Wall Street consolidated gains ahead of the weekend on Friday as climbing stocks sent the Standard & Poor's 500 index to its first ever close above 1,800.
Biogen & Gilead: Time To Ring the Cash Register?
Biotech darlings Biogen-Idec and Gilead Sciences zoomed higher today after getting some love from European regulators.
European CHMP Adopts Positive Opinion for Gilead Sciences' Sovaldi...
Gilead Sciences, Inc. today announced that the Committee for Medicinal Products for Human Use , the scientific committee of the European Medicines Agency , has adopted a positive opinion on the company's Marketing Authorisation Application for Sovaldi , an investigational once-daily oral nucleotide analogue polymerase inhibitor for the treatment of ... (more)
Biotech Stock Mailbag: Enanta, Vanda, Pharmacyclics, Top 2014 Stock Catalysts
Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.
Thu Nov 21, 2013
HIV and Hepatitis
HIV Integrase Inhibitor Elvitegravir Approved in European Union
The next-generation HIV integrase inhibitor elvitegravir has been approved by the European Commission, to be marketed under the brand name Vitekta, according to an announcement this week from developer Gilead Sciences.
Wed Nov 20, 2013
A Value Guru Is Loading Up On These 2 Biotech Stocks
It's a refrain you hear from many fund managers these days after witnessing the market grind ever higher.
Mon Nov 18, 2013
European Commission Approves Gilead's Vitektaa , an Integrase...
Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Vitekta tablets, an integrase inhibitor for the treatment of HIV-1 infection in adults without known mutations associated with resistance to elvitegravir.
Fri Nov 15, 2013
Traders Favorite: Gilead Sciences, Inc.(NASDAQ:GILD), Green Mountain...
Hot Stock Profits provides investors and traders with valuable trading tools and content as well as micro-cap stock alerts via eMail and text messages.
Wed Nov 13, 2013
Spotlights Washington State Biotech Leaders
Premier Life Science Companies Take Center Stage on Hotbed Map DENVER - Today BioSpace , the leading life sciences employment and news website, launched the 2013-2014 BioForest Hotbed campaign , highlighting Washington state's thriving biotechnology sector.
Tue Nov 12, 2013
Gilead Sciences to Present at the Credit Suisse 2013 Healthcare Conference on Wednesday, November 13
Gilead Sciences, Inc. today announced that its corporate presentation will be webcast from the Credit Suisse 2013 Healthcare Conference in Scottsdale, Arizona.
Gilead Sciences Leads In Rising Short Interest Among Biotechs
Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Alexion Pharmaceuticals grew by the largest percentages in late October.